Berberine Cancer Research Results

BBR, Berberine: Click to Expand ⟱
Features:

Berberine — Berberine is a protoberberine/isoquinoline alkaloid natural product found in plants such as Coptis, Berberis, and Phellodendron. It is a small-molecule phytochemical with pleiotropic metabolic, anti-inflammatory, and anticancer signaling effects rather than a single highly selective target profile. Its standard abbreviation is BBR. In oncology it is best classified as a multitarget natural-product lead compound and adjunct-sensitizer candidate, with strong preclinical evidence but no established standard anticancer regulatory use. Its translational profile is shaped by very low conventional oral bioavailability, extensive first-pass metabolism, broad tissue distribution, and substantial context dependence between cancer-cell pro-death effects and normal-cell cytoprotective redox effects.

Primary mechanisms (ranked):

  1. AMPK-centered metabolic stress with mitochondrial dysfunction, ATP depletion, and apoptosis/autophagy induction
  2. Suppression of aerobic glycolysis and hypoxia signaling, including HIF-1α, GLUT1, HK2, LDHA, and PKM2-linked tumor metabolism
  3. Anti-proliferative cell-cycle control with cyclin/CDK suppression and tumor suppressor reactivation
  4. Inhibition of PI3K/AKT, MAPK/ERK, JAK/STAT, and NF-κB inflammatory-survival signaling
  5. Anti-metastatic and anti-EMT activity via Wnt/β-catenin, TGF-β/Smad, FAK/RhoA/ROCK, MMPs, and CXCR4-related programs
  6. Pro-oxidant mitochondrial ROS elevation and ER-stress/caspase signaling in many cancer models, with opposite antioxidant/NRF2-supportive effects in some normal-cell and non-cancer settings
  7. Context-dependent chemosensitization and radiosensitization, including effects on hypoxia signaling and DNA-repair competence
  8. Emerging ferroptosis-related activity in some tumor models, but not a universal dominant mechanism across berberine biology

Bioavailability / PK relevance: Conventional oral berberine has poor systemic bioavailability, often cited as below 1% in animal studies, because of limited absorption, P-glycoprotein efflux, first-pass intestinal/hepatic metabolism, and self-aggregation. Human exposure is usually in the low ng/mL plasma range with conventional dosing, while multiple metabolites may contribute to activity. Tissue distribution can exceed plasma levels, but PK remains a major clinical translation constraint.

In-vitro vs systemic exposure relevance: Many anticancer in-vitro studies use roughly 10–100 µM, commonly around 20–50 µM, which usually exceeds readily achievable conventional plasma exposure after standard oral dosing. Therefore, direct translation of cell-culture potency to systemic monotherapy expectations is limited unless local gut exposure, tissue accumulation, metabolite contribution, formulation enhancement, or combination use is specifically relevant.

Clinical evidence status: Strong preclinical and mechanistic evidence; limited early human oncology/chemoprevention evidence; no established phase III anticancer efficacy standard and no mainstream regulatory approval as an anticancer drug. Current clinical relevance is best viewed as investigational and adjunct-oriented rather than proven standalone oncology therapy.

Berberine is a chemical found in some plants like European barberry, goldenseal, goldthread, Oregon grape, phellodendron, and tree turmeric. Berberine is a bitter-tasting and yellow-colored chemical.
Coptis (commonly referring to Coptidis Rhizoma, a traditional Chinese medicinal herb) contains bioactive alkaloids (most notably berberine and coptisine) that have been studied for their pharmacological effects—including their influence on reactive oxygen species (ROS) and related pathways.

– Berberine is known for its relatively low oral bioavailability, often cited at less than 1%. This low bioavailability is mainly due to poor intestinal absorption and active efflux by transport proteins such as P-glycoprotein.
– Despite the low bioavailability, berberine is still pharmacologically active, and its metabolites may also contribute to its overall effects.

• Effective Dosage in Studies
– Many clinical trials or preclinical studies use dosages in the range of 500 to 1500 mg per day, typically administered in divided doses.
– Therefore, to obtain a bioactive dose of berberine, supplementation in a standardized extract form is necessary.

-IC50 in cancer cell lines: Approximately 10–100 µM (commonly around 20–50 µM in many models)
-IC50 in normal cell lines: Generally higher (often above 100 µM), although this can vary with cell type
- In vivo studies: Dosing regimens in animal models generally range from about 50 to 200 mg/kg
- very effective AChE inhibitor (Alzheimers)
- Berberine may enhance the effects of blood-thinning medications like warfarin and aspirin.


-Note half-life reports vary 2.5-90hrs?.
-low solubility of apigenin in water : BioAv
Pathways:
- induce ROS production
- ROS↑ related: MMP↓(ΔΨm), ER Stress↑, Ca+2↑, Cyt‑c↑, Caspases↑, DNA damage↑, UPR↑, cl-PARP↑, HSP↓
- Lowers AntiOxidant defense in Cancer Cells: NRF2↓, GSH↓
- Raises AntiOxidant defense in Normal Cells: NRF2↑, SOD↑, GSH↑, Catalase↑,
- lowers Inflammation : NF-kB↓, COX2↓, p38↓, Pro-Inflammatory Cytokines : IL-1β↓, TNF-α↓, IL-6↓, IL-8↓
- PI3K/AKT(Inhibition), JAK/STATs, Wnt/β-catenin, AMPK, MAPK/ERK, and JNK.
- inhibit Growth/Metastases : , MMPs↓, MMP2↓, MMP9↓, IGF-1↓, uPA↓, VEGF↓, ROCK1↓, FAK↓, RhoA↓, NF-κB↓, CXCR4↓, TGF-β↓, α-SMA↓, ERK↓
- reactivate genes thereby inhibiting cancer cell growth : HDAC↓, DNMT1↓, EZH2↓, P53↑, HSP↓
- cause Cell cycle arrest : TumCCA↑, cyclin D1↓, cyclin E↓, CDK2↓, CDK4↓, CDK6↓,
- inhibits Migration/Invasion : TumCMig↓, TumCI↓, FAK↓, ERK↓,
- inhibits glycolysis /Warburg Effect and ATP depletion : HIF-1α↓, PKM2↓, cMyc↓, GLUT1↓, LDH↓, LDHA↓, HK2↓, PFKs↓, PDKs↓, Glucose↓, GlucoseCon↓
- inhibits angiogenesis↓ : VEGF↓, HIF-1α↓, Notch↓, FGF↓, PDGF↓, EGFR↓, Integrins↓,
- inhibits Cancer Stem Cells : CSC↓, Hh↓, GLi1↓, CD133↓, β-catenin↓, n-myc↓, sox2↓, notch2↓, nestin↓, OCT4↓,
- Others: PI3K↓, AKT↓, JAK↓, STAT↓, Wnt↓, β-catenin↓, AMPK↓, α↓, ERK↓, JNK,
- Synergies: chemo-sensitization, chemoProtective, RadioSensitizer, RadioProtective, Others(review target notes), Neuroprotective, Cognitive, Renoprotection, Hepatoprotective, CardioProtective,
- Selectivity: Cancer Cells vs Normal Cells

Rank Pathway / Target Axis Direction Primary Effect Notes / Cancer Relevance Ref
1 AMPK → mTOR axis ↑ AMPK / ↓ mTOR signaling Metabolic stress + growth suppression In vivo/in vitro colon tumorigenesis model: berberine activates AMPK, inhibits mTOR signaling and reduces proliferation/tumorigenesis, growth suppression, autophagy, HIF-1α ↓, glycolysis ↓, berberine’s known mitochondrial/energetic effects (ref)
2 Mitochondrial dysfunction / ROS generation ↑ ROS / mitochondrial stress Upstream metabolic trigger Berberine inhibits mitochondrial function, increases ROS, and contributes to AMPK activation and downstream apoptosis (ref)
3 Mitochondrial apoptosis (cytochrome c release) ↑ cytochrome c release Intrinsic death signaling Oral cancer model: berberine reduces mitochondrial membrane potential, releases cytochrome c, activates caspase-3 (ref)
4 Intrinsic apoptosis (caspase-3 activation) ↑ caspase-3 activation Programmed cell death Same oral cancer study documents caspase-3 activation as a key execution marker (ref)
5 NF-κB signaling (p65 activation) ↓ NF-κB activation Reduced pro-survival transcription Colon cancer model reports inhibition of p65 phosphorylation; interpreted as secondary to metabolic/redox stress (ref)
6 Cell cycle control ↑ G1 arrest Proliferation blockade Prostate cancer model: berberine induces G1-phase cell cycle arrest and caspase-3–dependent apoptosis (ref)
7 Hypoxia / glycolysis signaling (HIF-1α) ↓ HIF-1α protein Warburg / glycolysis suppression Berberine suppresses mTOR and reduces HIF-1α protein expression downstream of AMPK activation (ref)
8 Angiogenesis signaling (HIF-1α → VEGF axis) ↓ VEGF signaling Reduced vascular support Lung cancer study: berberine suppresses VEGF signaling alongside HIF-1α inhibition (ref)
9 PI3K–AKT–mTOR signaling ↓ PI3K / AKT / mTOR Survival pathway suppression Gastric cancer paper: berberine represses PI3K/AKT/mTOR signaling and improves chemosensitivity (ref)
10 Migration / invasion programs ↓ migration & invasion Anti-metastatic phenotype Tongue SCC model: berberine suppresses migration and invasion with associated signaling changes (ref)
11 Telomerase (hTERT) / immortalization axis ↓ hTERT-related signaling Reduced proliferative capacity Lung cancer study includes AP-2/hTERT regulatory axis modulation by berberine (ref)
12 In vivo tumor suppression ↓ tumorigenesis Demonstrated anti-tumor effect Colon tumorigenesis model confirms reduced proliferation and tumor burden with berberine (ref)


Scientific Papers found: Click to Expand⟱
2700- BBR,    Cell-specific pattern of berberine pleiotropic effects on different human cell lines
- in-vitro, GBM, U343 - in-vitro, GBM, MIA PaCa-2 - in-vitro, Nor, HDFa
selectivity↑, TumCCA↑, Casp3↑, TumCI↓, TumCMig↓, N-cadherin?, DNMT1↑,
2714- BBR,    Integrins and Cell Metabolism: An Intimate Relationship Impacting Cancer
AMPK↑, ITGB1↓,
2713- BBR,    Berberine improved the microbiota in lung tissue of colon cancer and reversed the bronchial epithelial cell changes caused by cancer cells
- in-vitro, Nor, BEAS-2B
*GutMicro↑, *IL6↑, *IL10↑, *IL17↑, *IFN-γ↑, PDGF↓, *RAD51↓,
2712- BBR,    Suppression of colon cancer growth by berberine mediated by the intestinal microbiota and the suppression of DNA methyltransferases (DNMTs)
- in-vitro, Colon, HT29 - in-vivo, NA, NA
TumCG↓, GutMicro↑, other↝, IL10↓, cMyc↓, DNMT1↓, DNMTs↓,
2711- BBR,    Berberine inhibits the progression of breast cancer by regulating METTL3-mediated m6A modification of FGF7 mRNA
- in-vitro, BC, MCF-7 - in-vitro, BC, MDA-MB-231 - in-vivo, NA, NA
TumCP↓, TumCI↓, TumCMig↓, Apoptosis↑, FGF↓, IGFBP3↑,
2710- BBR,    Berberine inhibits the Warburg effect through TET3/miR-145/HK2 pathways in ovarian cancer cells
- in-vitro, Ovarian, SKOV3
Warburg↓, miR-145↑, HK2↓, TET3↑, Glycolysis↓, PKM2↓, GLUT1↓, LDH↓, PFK2↓, PDK1↓,
2709- BBR,    Berberine inhibits the glycolysis and proliferation of hepatocellular carcinoma cells by down-regulating HIF-1α
- in-vitro, HCC, HepG2
TumCP↓, TumCMig↓, TumCI↓, Apoptosis↑, Glycolysis↓, Hif1a↓, GLUT1↓, HK2↓, PKM2↓, LDHA↓,
2708- BBR,    Berberine decelerates glucose metabolism via suppression of mTOR‑dependent HIF‑1α protein synthesis in colon cancer cells
- in-vitro, CRC, HCT116
TumCG↓, GlucoseCon↓, GLUT1↓, LDHA↓, HK2↓, Hif1a↓, mTOR↓, Glycolysis↓,
2707- BBR,    Berberine exerts its antineoplastic effects by reversing the Warburg effect via downregulation of the Akt/mTOR/GLUT1 signaling pathway
- in-vitro, Liver, HepG2 - in-vitro, BC, MCF-7
GLUT1↓, Akt↓, mTOR↓, ATP↓, GlucoseCon↓, TumCP↓, Warburg↓, selectivity↑, TumCCA↑, Glycolysis↓,
2706- BBR,    Berberine Inhibits Growth of Liver Cancer Cells by Suppressing Glutamine Uptake
- in-vitro, HCC, Hep3B - in-vitro, HCC, Bel-7402 - in-vivo, NA, NA
TumCP↓, glut↓, SLC12A5↓, cMyc↓, GLS↓,
2705- BBR,    Mechanism underlying berberine's effects on HSP70/TNFα under heat stress: Correlation with the TATA boxes
- in-vivo, Nor, NA - in-vitro, Nor, PC12
HSP70/HSPA5↓, TNF-α↓,
2704- BBR,    Inhibitory Effect of Berberine on Zeste Homolog 2 (Ezh2) Enhancement in Human Esophageal Cell Lines
- in-vitro, ESCC, KYSE450
EZH2↓, AXL↓,
2703- BBR,  CUR,  SFN,  UA,  GamB  Naturally occurring anti-cancer agents targeting EZH2
- Review, Var, NA
EZH2↓,
2702- BBR,    The enhancement of combination of berberine and metformin in inhibition of DNMT1 gene expression through interplay of SP1 and PDPK1
- in-vitro, Lung, A549 - in-vitro, Lung, H1975
TumCG↓, MAPK↓, FOXO3↑, TumCCA↑, TumCMig↓, TumCI↓, Sp1/3/4↓, PDK1↓, DNMT1↓, eff↑,
2701- BBR,    Berberine Inhibits KLF4 Promoter Methylation and Ferroptosis to Ameliorate Diabetic Nephropathy in Mice
- in-vivo, Diabetic, NA
*Inflam↓, *antiOx↑, *Ferroptosis↓, *RenoP↑, *DNMT1↓, *DNMTs↓, *KLF4↑,
2715- BBR,  Rad,    Berberine Can Amplify Cytotoxic Effect of Radiotherapy by Targeting Cancer Stem Cells
- in-vitro, BC, MCF-7
tumCV↓, OCT4↓, SOX2↓, RadioS↑, CSCs↓,
2699- BBR,    Plant Isoquinoline Alkaloid Berberine Exhibits Chromatin Remodeling by Modulation of Histone Deacetylase To Induce Growth Arrest and Apoptosis in the A549 Cell Line
- in-vitro, Lung, A549
HDAC↓, TumCCA↑, TNF-α↓, COX2↓, MMP2↓, MMP9↓, P21↑, P53↑, Casp↑, ac‑H3↑, ac‑H4↑, ROS↑, MMP↓,
2698- BBR,    A gene expression signature-based approach reveals the mechanisms of action of the Chinese herbal medicine berberine
- Analysis, BC, MDA-MB-231
HDAC↓, Akt↓, mTOR↓, ER Stress↑, TumAuto↑, AMPK↑, mTOR∅, HDAC∅, ac‑α-tubulin↑,
2697- BBR,    Structural exploration of common pharmacophore based berberine derivatives as novel histone deacetylase inhibitor targeting HDACs enzymes
- Analysis, Var, NA
HDAC↓,
2696- BBR,    Berberine regulates proliferation, collagen synthesis and cytokine secretion of cardiac fibroblasts via AMPK-mTOR-p70S6K signaling pathway
- in-vivo, Nor, NA
*α-SMA↓, *TGF-β1↓, *IL10↑, *p‑AMPK↑, *p‑mTOR↓, *P70S6K↓, *cardioP↑,
2695- BBR,    The effects of Berberis vulgaris consumption on plasma levels of IGF-1, IGFBPs, PPAR-γ and the expression of angiogenic genes in women with benign breast disease: a randomized controlled clinical trial
- Trial, BC, NA
IGF-1↓, PPARγ↓, VEGF↓, Hif1a↓, angioG↓,
2694- BBR,    Berberine down-regulates IL-8 expression through inhibition of the EGFR/MEK/ERK pathway in triple-negative breast cancer cells
- in-vitro, BC, NA
IL8↓, TumCI↓, EGFR↓, MEK↓, ERK↓, TGF-β1↓, VEGF↓,
2693- BBR,    Antitumor Effects of Berberine on Gliomas via Inactivation of Caspase-1-Mediated IL-1β and IL-18 Release
- in-vitro, GBM, U251 - in-vitro, GBM, U87MG
Casp1↓, ERK↓, IL1β↓, IL18↓, EMT↑,
2692- BBR,    Berberine affects osteosarcoma via downregulating the caspase-1/IL-1β signaling axis
- in-vitro, OS, MG63 - in-vitro, OS, SaOS2 - in-vivo, NA, NA
Casp1↓, IL1β↓, TumCG↓, Dose↝, Apoptosis↑, Inflam↓,
2691- BBR,    Berberine induces FasL-related apoptosis through p38 activation in KB human oral cancer cells
- in-vitro, Oral, KB
tumCV↓, DNAdam↑, Casp3↑, Casp7↑, FasL↑, Casp8↑, Casp9↑, PARP↑, BAX↑, BAD↑, APAF1↑, MMP2↓, MMP9↓, p‑p38↑, ERK↑, MAPK↑,
2690- BBR,    Berberine Differentially Modulates the Activities of ERK, p38 MAPK, and JNK to Suppress Th17 and Th1 T Cell Differentiation in Type 1 Diabetic Mice
- in-vivo, Diabetic, NA
*Inflam↓, *Th17↓, *Th1 response↓, *ERK↑, *p38↓, *JNK↓, *STAT1↓, *STAT4↓, *MAPK↓,
2689- BBR,    Berberine protects against glutamate-induced oxidative stress and apoptosis in PC12 and N2a cells
- in-vitro, Nor, PC12 - in-vitro, AD, NA - in-vitro, Stroke, NA
*ROS↓, *lipid-P↓, *DNAdam↓, *GSH↑, *SOD↑, *eff↑, *cl‑Casp3↓, *BAX↓, *neuroP↑, *Dose↝, *Ca+2↓,
2686- BBR,    Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs
- Review, Nor, NA
Inflam↓, IL6↓, MCP1↓, COX2↓, PGE2↓, MMP2↓, MMP9↓, DNAdam↑, eff↝, Telomerase↓, Bcl-2↓, AMPK↑, ROS↑, MMP↓, ATP↓, p‑mTORC1↓, p‑S6K↓, ERK↓, PI3K↓, PTEN↑, Akt↓, Raf↓, MEK↓, Dose↓, Dose↑, selectivity↑, TumCCA↑, eff↑, EGFR↓, Glycolysis↓, Dose?, p27↑, CDK2↓, CDK4↓, cycD1/CCND1↓, cycE/CCNE↓, Bax:Bcl2↑, Casp3↑, Casp9↑, VEGFR2↓, ChemoSen↑, eff↑, eff↑, PGE2↓, JAK2↓, STAT3↓, CXCR4↓, CCR7↓, uPA↓, CSCs↓, EMT↓, Diff↓, CD133↓, Nestin↓, n-MYC↓, NOTCH↓, SOX2↓, Hif1a↓, VEGF↓, RadioS↑,
2685- BBR,    Berberine induces neuronal differentiation through inhibition of cancer stemness and epithelial-mesenchymal transition in neuroblastoma cells
- in-vitro, neuroblastoma, NA
CSCs↓, CD133↓, β-catenin/ZEB1↓, n-MYC↓, SOX2↓, NOTCH2↓, Nestin↓, TumCCA↑, TumCP↓, CDK1↓, Cyc↓, Apoptosis↑, Bax:Bcl2↑, NCAM↓, MMP2↓, MMP9↓, *Smad1↑, *HSP70/HSPA5↑, *LAMs↑,
2684- BBR,    Berberine is a Novel Mitochondrial Calcium Uniporter Inhibitor that Disrupts MCU‐EMRE Assembly
- in-vivo, Nor, NA
*MCU↓, *mt-Ca+2↓, *cardioP↑,
4275- BBR,    Pharmacological effects of berberine on mood disorders
- Review, NA, NA
*antiOx↑, *Inflam↓, *hepatoP↑, *eff↑, *5HT↑, *Mood↑, *BDNF↑,
5548- BBR,    Berbamine induces SMMC-7721 cell apoptosis via upregulating p53, downregulating survivin expression and activating mitochondria signaling pathway
- in-vitro, HCC, SMMC-7721 cell
TumCG↓, Apoptosis↑, Cyt‑c↑, BAX↑, P53↑, Bcl-2↓, survivin↓,
5545- BBR,    Improving the oral bioavailability of berberine: A crystal engineering approach
- in-vivo, Nor, NA
BioAv↑,
5182- BBR,    Berberine suppresses in vitro migration and invasion of human SCC-4 tongue squamous cancer cells through the inhibitions of FAK, IKK, NF-κB, u-PA and MMP-2 and -9
- in-vitro, SCC, SCC4
TumCMig↓, TumCI↓, p‑JNK↝, p‑ERK↝, p‑p38↝, IKKα↝, NF-kB↝, MMP2↓, MMP9↓,
5181- BBR,  Cisplatin,    Berberine Improves Chemo-Sensitivity to Cisplatin by Enhancing Cell Apoptosis and Repressing PI3K/AKT/mTOR Signaling Pathway in Gastric Cancer
- in-vitro, GC, SGC-7901 - in-vitro, GC, BGC-823
tumCV↓, MDR1↓, ChemoSen↑, PI3K↓, Akt↓, mTOR↓,
5180- BBR,    Berberine Targets AP-2/hTERT, NF-κB/COX-2, HIF-1α/VEGF and Cytochrome-c/Caspase Signaling to Suppress Human Cancer Cell Growth
- in-vitro, NSCLC, NA
TumCMig↓, TumCP↓, Apoptosis↑, TFAP2A↓, hTERT/TERT↓, NF-kB↓, COX2↓, Hif1a↓, VEGF↓, Akt↓, p‑ERK↓, Cyt‑c↑, cl‑Casp↑, cl‑PARP↑, PI3K↓, Akt↓, Raf↓, MEK↓, ERK↓,
5179- BBR,    Regulation of Cell Signaling Pathways by Berberine in Different Cancers: Searching for Missing Pieces of an Incomplete Jig-Saw Puzzle for an Effective Cancer Therapy
- Review, Var, NA
AMPK↑, Casp3↑, cl‑PARP↑, Mcl-1↓, cFLIP↓, β-catenin/ZEB1↓, Wnt↓, STAT3↓, mTOR↓, Hif1a↓, NF-kB↓, SIRT1↑, DNMT1↓, DNMT3A↓, miR-29b↓, IGFBP1↑, eff↑, chemoPv↑, BioAv↓,
5178- BBR,    Berberine, a natural product, induces G1-phase cell cycle arrest and caspase-3-dependent apoptosis in human prostate carcinoma cells
- in-vitro, Pca, DU145 - in-vitro, Pca, PC3
TumCP↑, TumCCA↑, cycD1/CCND1↓, cycE/CCNE↓, CDK2↓, CDK4↓, CDK6↓, P21↑, p27↑, Apoptosis↑, Bax:Bcl2↑, MMP↓, Casp9↑, Casp3↑, PARP↑, DNAdam↑, selectivity↑, Cyt‑c↑,
5177- BBR,    Berberine induces apoptosis in human HSC-3 oral cancer cells via simultaneous activation of the death receptor-mediated and mitochondrial pathway
- in-vitro, Oral, HMC3
TumCCA↑, Apoptosis↑, TumCG↓, Casp3↑, TumCCA↑, ROS↑, Ca+2↑, MMP↓, ER Stress↑, Cyt‑c↑,
5176- BBR,    Berberine regulates AMP-activated protein kinase signaling pathways and inhibits colon tumorigenesis in mice
- vitro+vivo, CRC, HCT116 - in-vitro, CRC, SW480 - in-vitro, CRC, LoVo
TumVol↓, Ki-67↓, COX2↓, AMPK↑, mTOR↓, NF-kB↓, cycD1/CCND1↓, survivin↓, P53↑, cl‑Casp3↑, TumCP↓, Inflam↓, COX2↓, ACC↑,
4658- BBR,    Berberine Suppresses Stemness and Tumorigenicity of Colorectal Cancer Stem-Like Cells by Inhibiting m6A Methylation
- in-vitro, CRC, HCT116 - in-vitro, CRC, HT29
CSCs↓, TumCP↓, cycD1/CCND1↓, p27↑, P21↑, TumCCA↑, Apoptosis↑, ChemoSen↑, β-catenin/ZEB1↓, FTO↑, CD44↓, CD133↓, ChemoSen↑,
4340- BBR,    Agonist-dependent differential effects of berberine in human platelet aggregation
- Human, NA, NA
*AntiAg↑, *other?,
4300- BBR,    Effect of berberine on cognitive function and β-amyloid precursor protein in Alzheimer’s disease models: a systematic review and meta-analysis
- Review, AD, NA
*APP↓, *cognitive↑, *Aβ↓, *BACE↓, *tau?,
4299- BBR,    Berberine attenuates cognitive impairment and ameliorates tau hyperphosphorylation by limiting the self-perpetuating pathogenic cycle between NF-κB signaling, oxidative stress and neuroinflammation
- in-vivo, AD, NA
*memory↑, *p‑tau↓, *NF-kB↓, *GSH↑, *lipid-P↓, *cognitive↑, *ROS↓, *Inflam↓,
4298- BBR,    Berberine mitigates cognitive decline in an Alzheimer’s Disease Mouse Model by targeting both tau hyperphosphorylation and autophagic clearance
- in-vivo, AD, NA
*cognitive↑, *p‑tau↓, *GSK‐3β↓, *PP2A↑, *memory↑, *Akt↑, *LC3II↑, *Beclin-1↑,
2683- BBR,    Berberine reduces endoplasmic reticulum stress and improves insulin signal transduction in Hep G2 cells
- in-vitro, Liver, HepG2
JNK↓, p‑PERK↓, p‑eIF2α↓, *ER Stress↓,
4274- BBR,    Berberine exerts antidepressant effects in vivo and in vitro through the PI3K/AKT/CREB/BDNF signaling pathway
- in-vivo, NA, NA
*IL1β↓, *IL6↓, *TNF-α↓, *CRP↓, *CREB↑, *BDNF↑,
3833- BBR,    Traditional Chinese Medicine: Role in Reducing β-Amyloid, Apoptosis, Autophagy, Neuroinflammation, Oxidative Stress, and Mitochondrial Dysfunction of Alzheimer’s Disease
- Review, AD, NA
*cardioP↑, *neuroP↑, *memory↑, *Aβ↓,
3754- BBR,  CUR,  EGCG,  Hup,    Traditional Chinese medicinal herbs as potential AChE inhibitors for anti-Alzheimer’s disease: A review
*AChE↓, *Aβ↓, *LDL↓, *RenoP↑, *BChE↓, *eff↑, *BACE↓, *AChE↓, *eff↑,
3749- BBR,    Anti-Alzheimer and Antioxidant Activities of Coptidis Rhizoma Alkaloids
- Review, AD, NA
*antiOx↑, *AChE↓, *BChE?,

Showing Research Papers: 1 to 50 of 119
Page 1 of 3 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 119

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

ROS↑, 3,  

Mitochondria & Bioenergetics ⓘ

ATP↓, 2,   MEK↓, 3,   MMP↓, 4,   Raf↓, 2,  

Core Metabolism/Glycolysis ⓘ

ACC↑, 1,   AMPK↑, 5,   cMyc↓, 2,   GLS↓, 1,   GlucoseCon↓, 2,   glut↓, 1,   Glycolysis↓, 5,   HK2↓, 3,   LDH↓, 1,   LDHA↓, 2,   PDK1↓, 2,   PFK2↓, 1,   PKM2↓, 2,   PPARγ↓, 1,   p‑S6K↓, 1,   SIRT1↑, 1,   Warburg↓, 2,  

Cell Death ⓘ

Akt↓, 6,   APAF1↑, 1,   Apoptosis↑, 9,   BAD↑, 1,   BAX↑, 2,   Bax:Bcl2↑, 3,   Bcl-2↓, 2,   Casp↑, 1,   cl‑Casp↑, 1,   Casp1↓, 2,   Casp3↑, 6,   cl‑Casp3↑, 1,   Casp7↑, 1,   Casp8↑, 1,   Casp9↑, 3,   cFLIP↓, 1,   Cyt‑c↑, 4,   FasL↑, 1,   hTERT/TERT↓, 1,   JNK↓, 1,   p‑JNK↝, 1,   MAPK↓, 1,   MAPK↑, 1,   Mcl-1↓, 1,   p27↑, 3,   p‑p38↑, 1,   p‑p38↝, 1,   survivin↓, 2,   Telomerase↓, 1,  

Kinase & Signal Transduction ⓘ

Sp1/3/4↓, 1,  

Transcription & Epigenetics ⓘ

EZH2↓, 2,   ac‑H3↑, 1,   ac‑H4↑, 1,   miR-145↑, 1,   other↝, 1,   TET3↑, 1,   tumCV↓, 3,  

Protein Folding & ER Stress ⓘ

p‑eIF2α↓, 1,   ER Stress↑, 2,   HSP70/HSPA5↓, 1,   p‑PERK↓, 1,  

Autophagy & Lysosomes ⓘ

TumAuto↑, 1,  

DNA Damage & Repair ⓘ

DNAdam↑, 3,   DNMT1↓, 3,   DNMT1↑, 1,   DNMT3A↓, 1,   DNMTs↓, 1,   P53↑, 3,   PARP↑, 2,   cl‑PARP↑, 2,  

Cell Cycle & Senescence ⓘ

CDK1↓, 1,   CDK2↓, 2,   CDK4↓, 2,   Cyc↓, 1,   cycD1/CCND1↓, 4,   cycE/CCNE↓, 2,   P21↑, 3,   TFAP2A↓, 1,   TumCCA↑, 10,  

Proliferation, Differentiation & Cell State ⓘ

CD133↓, 3,   CD44↓, 1,   CSCs↓, 4,   Diff↓, 1,   EMT↓, 1,   EMT↑, 1,   ERK↓, 4,   ERK↑, 1,   p‑ERK↓, 1,   p‑ERK↝, 1,   FGF↓, 1,   FOXO3↑, 1,   HDAC↓, 3,   HDAC∅, 1,   IGF-1↓, 1,   IGFBP1↑, 1,   IGFBP3↑, 1,   mTOR↓, 6,   mTOR∅, 1,   p‑mTORC1↓, 1,   n-MYC↓, 2,   Nestin↓, 2,   NOTCH↓, 1,   NOTCH2↓, 1,   OCT4↓, 1,   PI3K↓, 3,   PTEN↑, 1,   SOX2↓, 3,   STAT3↓, 2,   TumCG↓, 6,   Wnt↓, 1,  

Migration ⓘ

AXL↓, 1,   Ca+2↑, 1,   FTO↑, 1,   ITGB1↓, 1,   Ki-67↓, 1,   miR-29b↓, 1,   MMP2↓, 5,   MMP9↓, 5,   N-cadherin?, 1,   NCAM↓, 1,   PDGF↓, 1,   TGF-β1↓, 1,   TumCI↓, 6,   TumCMig↓, 6,   TumCP↓, 8,   TumCP↑, 1,   uPA↓, 1,   ac‑α-tubulin↑, 1,   β-catenin/ZEB1↓, 3,  

Angiogenesis & Vasculature ⓘ

angioG↓, 1,   EGFR↓, 2,   Hif1a↓, 6,   VEGF↓, 4,   VEGFR2↓, 1,  

Barriers & Transport ⓘ

GLUT1↓, 4,   SLC12A5↓, 1,  

Immune & Inflammatory Signaling ⓘ

CCR7↓, 1,   COX2↓, 5,   CXCR4↓, 1,   IKKα↝, 1,   IL10↓, 1,   IL18↓, 1,   IL1β↓, 2,   IL6↓, 1,   IL8↓, 1,   Inflam↓, 3,   JAK2↓, 1,   MCP1↓, 1,   NF-kB↓, 3,   NF-kB↝, 1,   PGE2↓, 2,   TNF-α↓, 2,  

Hormonal & Nuclear Receptors ⓘ

CDK6↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 1,   BioAv↑, 1,   ChemoSen↑, 4,   Dose?, 1,   Dose↓, 1,   Dose↑, 1,   Dose↝, 1,   eff↑, 5,   eff↝, 1,   MDR1↓, 1,   RadioS↑, 2,   selectivity↑, 4,  

Clinical Biomarkers ⓘ

EGFR↓, 2,   EZH2↓, 2,   GutMicro↑, 1,   hTERT/TERT↓, 1,   IL6↓, 1,   Ki-67↓, 1,   LDH↓, 1,  

Functional Outcomes ⓘ

chemoPv↑, 1,   TumVol↓, 1,  
Total Targets: 176

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 3,   Ferroptosis↓, 1,   GSH↑, 2,   lipid-P↓, 2,   ROS↓, 2,   SOD↑, 1,  

Core Metabolism/Glycolysis ⓘ

p‑AMPK↑, 1,   CREB↑, 1,   LDL↓, 1,   MCU↓, 1,  

Cell Death ⓘ

Akt↑, 1,   BAX↓, 1,   cl‑Casp3↓, 1,   Ferroptosis↓, 1,   JNK↓, 1,   MAPK↓, 1,   p38↓, 1,  

Transcription & Epigenetics ⓘ

other?, 1,  

Protein Folding & ER Stress ⓘ

ER Stress↓, 1,   HSP70/HSPA5↑, 1,  

Autophagy & Lysosomes ⓘ

Beclin-1↑, 1,   LC3II↑, 1,  

DNA Damage & Repair ⓘ

DNAdam↓, 1,   DNMT1↓, 1,   DNMTs↓, 1,   RAD51↓, 1,  

Proliferation, Differentiation & Cell State ⓘ

ERK↑, 1,   GSK‐3β↓, 1,   KLF4↑, 1,   p‑mTOR↓, 1,   P70S6K↓, 1,   STAT1↓, 1,   STAT4↓, 1,  

Migration ⓘ

AntiAg↑, 1,   APP↓, 1,   Ca+2↓, 1,   mt-Ca+2↓, 1,   LAMs↑, 1,   Smad1↑, 1,   TGF-β1↓, 1,   α-SMA↓, 1,  

Immune & Inflammatory Signaling ⓘ

CRP↓, 1,   IFN-γ↑, 1,   IL10↑, 2,   IL17↑, 1,   IL1β↓, 1,   IL6↓, 1,   IL6↑, 1,   Inflam↓, 4,   NF-kB↓, 1,   Th1 response↓, 1,   Th17↓, 1,   TNF-α↓, 1,  

Synaptic & Neurotransmission ⓘ

5HT↑, 1,   AChE↓, 3,   BChE?, 1,   BChE↓, 1,   BDNF↑, 2,   tau?, 1,   p‑tau↓, 2,  

Protein Aggregation ⓘ

Aβ↓, 3,   BACE↓, 2,   PP2A↑, 1,  

Drug Metabolism & Resistance ⓘ

Dose↝, 1,   eff↑, 4,  

Clinical Biomarkers ⓘ

CRP↓, 1,   GutMicro↑, 1,   IL6↓, 1,   IL6↑, 1,  

Functional Outcomes ⓘ

cardioP↑, 3,   cognitive↑, 3,   hepatoP↑, 1,   memory↑, 3,   Mood↑, 1,   neuroP↑, 2,   RenoP↑, 2,  
Total Targets: 76

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:41  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page